Antibodies binding AXL
AssigneeGenmab A/S
InventorsEsther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Claims21
An antibody which binds to AXL and comprises at least one binding region comprising a pair of variable heavy chain (VH) and variable light chain (VL) regions selected from the group consisting of:
- a) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 83, 84, and 85, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 86, the sequence GAS, and SEQ ID NO:
- 87, respectively;
- b) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 88, 89, and 90, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 91, the sequence GAS, and SEQ ID NO:
- 92, respectively;
- c) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 93, 94, and 95, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 96, the sequence GAS, and SEQ ID NO:
- 97, respectively;
- d) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 98, 99, and 100, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 101, the sequence DAS, and SEQ ID NO:
- 102, respectively;
- e) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS:
- 103, 104, and 105, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 106, the sequence GAS, and SEQ ID NO:
- 107, respectively;
- f) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 93, 94, and 95, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 128, the sequence XAS, wherein X is D or G, and SEQ ID NO:
- 129, respectively;
- and
- g) a VH region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 93, 126, and 127, respectively, and a VL region comprising the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 96, the sequence GAS, and SEQ ID NO:
- 97.
An antibody which binds to AXL and comprises at least one binding region comprising variable heavy chain (VH) and variable light chain (VL) regions selected from the group consisting of:
- a) VH and VL regions comprising the amino acid sequences of SEQ ID NOs:
- 25 and 26, respectively;
- b) VH and VL regions comprising the amino acid sequences of SEQ ID NOs:
- 21 and 22, respectively;
- c) VH and VL regions comprising the amino acid sequences of SEQ ID NOs:
- 23 and 24, respectively;
- d) VH and VL regions comprising the amino acid sequences of SEQ ID NOs:
- 27 and 28, respectively;
- and
- e) VH and VL regions comprising the amino acid sequences of SEQ ID NOs:
- 29 and 30, respectively.
Dependencies are inferred from the claim text.